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Summary
Background. Injecting drug use (IDU) is the major driver of Hepatitis C Virus (HCV) infection in European and other 
developed countries.  People who inject drugs (PWID) and prisoners, both marginalised and underserved populations are 
recognised as key groups to target for HCV screening and treatment. Aim: To review the most up to date published litera-
ture on HCV screening in PWID and prisoners. Methods: Electronic data base (Medline, PubMed, Cochrane library and 
Embase) and relevant website search using key search terms related to the topic. Results: Data on HCV screening in these 
two groups is incomplete. Over half of PWID and a quarter of prisoners globally have been exposed to HCV. Multiple 
personal and institutional barriers, including; lack of knowledge, fear, stigma, complex testing procedures and competing 
priorities, have been identiied to the upscaling of screening in these two groups. Focussed screening at targeted locations, 
increasing screening methods including the use of dried blood spot testing (DBS), peer-worker involvement  and opt-out 
screening in prisons has the potential to enable uptake. Relex-RNA testing streamlines identiication of active infection 
and improves linkage to care.  Supporting community linkage on prison release is critical to optimise HCV management. 
Active case inding in PWID and prisoners, provided within an ethical and human rights framework, increases diagnosis, 
assessment, and treatment, reduces transmission and is cost-effective. Conclusion: Optimising HCV screening in PWID 
and prisoners underpins any public and prison health strategy aimed at HCV elimination but requires political will and 
targeted resources to be successfully implemented. 
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1. Introduction
Global HCV related morbidity and mortal-
ity continues to increase [22, 64]. HCV infection is 
mainly a disease of poor and marginalised people 
with the majority of those infected unaware of their 
status and not linked with traditional medical services 
[17, 53]. 
Many of those infected are diagnosed years af-
ter the initial exposure and often when symptomatic 
for advanced liver disease [17, 22, 53, 64, 78]. Late 
diagnosis of HCV infection is associated with poor 
outcomes and with increased risk of onward trans-
mission [64, 78]. The diagnosis of HCV infection can 
be associated with a positive change in drug and risk-
taking behaviour and can identify patients who can be 
linked with treatment [12]. 
Screening for HCV infection is based on detec-
tion of anti-HCV antibodies by enzyme immunoassay 
and conirmation of active disease by Nucleic Acid 
Test (NAT) for HCV RNA [34]. Both tests are widely 
available as validated commercial assays and can be 
laboratory or point of care (POC) based. Genotyp-
ing is usually carried out following sequencing of the 
5’ untranslated region (5'UTR) of the non-structural 
protein 5B (NS5B) region of the HCV genome [34]. 
Pacini Editore & AU CNS
HEROIN ADDICTION &
RELATED CLINICAL
PROBLEMS
www.europad.org
www.wftod.org
- 36 -
Heroin Addiction and Related Clinical Problems 21(1): 35-45
In low and middle incomes countries, the main 
route of HCV transmission is iatrogenic while in high 
income countries, the highest prevalence of infection 
occurs among people who inject drugs [78]. They also 
contribute not insigniicantly to HCV transmission in 
developing countries [78]. More recently an increas-
ing prevalence of HCV infection has been identiied 
in HIV positive men who have sex with men (MSM) 
[11]. 
PWID include those who have ever injected 
an illicit drug. This population consists of both past 
injectors and “recent” injectors (with deinitions for 
“recent” varying in the literature from 1 month to 1 
year) [43]. A subgroup of PWID will also be receiv-
ing agonist opioid treatment (AOT), some of whom 
will continue to inject drugs [43]. 
In the literature PWID and prisoners are often 
reported as two separate groups [43, 44].  This sepa-
ration is artiicial because HCV infected prison popu-
lations are mainly a sub-group of the PWID popula-
tion (past and present injectors) [44, 80].
The ongoing criminalisation of drug users en-
sures PWID experience high incarceration rates (56-
90% ever being incarcerated) and previous incarcera-
tion is associated frequently with HCV infection and 
increased injecting risk in the community [75, 80]. 
This group move between community and prison 
with continued exposure to risk factors and often 
experiencing similar barriers to HCV screening and 
treatment in both settings [4, 66, 75, 80]. 
Recent prison release is also associated with 
heightened transmission risk [65]. Transitioning from 
prison to community is identiied as high risk and 
seen as crucial to understanding HCV transmission 
and linkage to care in the community [15, 65].  This 
is the rationale for including both groups in this lit-
erature review.
Despite PWID and prisoners being identiied as 
groups at high risk of HCV infection, screening rates 
remain low, with most unaware of their status [25, 
48, 80]. PWID experience many barriers, including 
stigma, to engaging in traditional medical services 
[66]. Only half of the infected PWID in the USA and 
the UK are diagnosed [48]. High prevalence in this 
cohort, coupled with low awareness of infection, con-
tributes to further transmission [48, 49]. 
Despite having access to health care while in 
prison, the majority of prisoners do not access HCV 
screening or treatment services [25, 60]. In many 
countries prison HCV screening programs are spo-
radic and incomplete [24, 42, 44, 60, 80]. In the US, 
75% of state prisons offer no screening or targeted 
screening based on disclosed risk behaviour [42]. In 
many countries, prisoners constitute a considerable 
gap in the tested population [25, 44].
Recent developments in HCV management are 
relected in a discourse of optimism for those infect-
ed. The management of HCV infection has evolved 
considerably in the past ive years with the develop-
ment of non-interferon based direct acting anti-virals 
(DAA) [28]. These therapies have meant a signiicant 
reduction in treatment duration; adverse side effects 
experienced by patients and signiicantly improved 
treatment outcomes for all genotypes [28, 33].
The review encompasses HCV incidence, preva-
lence and screening in both PWID and prisoners. The 
screening component includes barriers and enablers, 
guidelines, interventions/models designed to increase 
uptake, outcomes and cost-effectiveness. 
2. Methods
A narrative review of the literature was under-
taken. The search engines Medline, PubMed, the 
Cochrane Library and Embase were searched for all 
articles published in the time frame 2008-2018 in all 
languages.  Key search terms used were prison, pris-
oner, inmate combined with Hepatitis C and a range 
of other terms relevant to HCV case inding, includ-
ing incidence, prevalence, screening and cost-effec-
tiveness. The same search was repeating replacing 
prisoner with PWID.
Due to the recent advances in HCV management, 
preference was given to systematic reviews, articles 
published in the last 5 years and in high impact peer 
reviewed journals. The reference lists of the chosen 
publications were also searched for additional articles 
that might be relevant to the review. Websites from 
the following organisations; United Nations Ofice on 
Drugs and Crime (UNDOC), World Health Organi-
sation (WHO), European Centre for Disease Preven-
tion and Control (ECDC), European Monitoring Cen-
tre for Drugs and Drug Addiction (EMCDDA) and 
Centre for Disease Control and Prevention (CDC). 
Reference lists from these reports were searched for 
additional articles relevant to this review. Grey and 
unpublished literature was not included. 
The term prison is used in this review to encom-
pass all places of detention associated with the crimi-
nal justice system, including prisons, remand centres 
(prisoners awaiting trial) and the American term jail 
(prisoners on remand and serving sentences of less 
than one year), juvenile detention facilities, pre-trial 
detention centres and extra-judicial detention centres 
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for PWID.
3. Results
3.1. Epidemiology of HCV among PWID and 
prisoners
There are large deicits in information regard-
ing HCV infection and its management in most juris-
dictions [22, 53]. This deicit in surveillance is even 
greater among PWID and prison populations [25, 44, 
71].
There is much regional variation in prevalence, 
but it is estimated that 65% of PWID (> 10 million 
people) have been infected with HCV [25]. Across 
Europe the prevalence of anti-HCV among PWID 
ranges from 15%-84%, with an average almost 50 
times higher than the general population [27, 35]. 
Similar high anti-HCV prevalence rates among PWID 
are reported in Australia and USA [32, 48].
Since PWID are over represented in prison pop-
ulations, there is a much higher HCV prevalence rate 
in prisoners than in the general population [44, 71]. 
A 2008 review found a chronic HCV prevalence of 
16%-49% in prison populations globally [71]. This 
review of 30 HCV prison- based seroprevalence stud-
ies in 14 countries reported that most countries had an 
anti-HCV prevalence of between 30-40% and found 
that prisoners with a history of IDU were approxi-
mately 24 times more likely than non-IDU to have 
been exposed to HCV [71]. The odds ratio of being 
anti- HCV positive was three times higher for inmates 
exposed to tattooing than those not exposed [71].
A more recent 2013 systematic review and me-
ta-analysis of the incidence and prevalence of HCV 
infection in prison and closed settings found an HCV 
incidence among general detainees of 1.4 per 100-per-
son years and 16.4 per 100-person years in detainees 
with a history of IDU [44]. This review reports a sum-
mary HCV prevalence estimate for general detainees 
of 26%, increasing to 64% in those with a history of 
IDU [44]. 
There are marked regional variations in HCV 
prevalence estimates among prisoners. The low-
est rates are found in the Middle East and North 
Africa (3%) with the highest rates found in Central 
Asia (38%) [44]. Studies reporting on HCV preva-
lence in prisoners with a history of IDU found lower 
rates of infection in Latin American countries (23%) 
and highest in Western Europe (73%) (Larney et al. 
2013). There are an estimated 2.2 million detainees 
globally infected with HCV with the largest numbers 
being in North America (668,500) and East and South 
East Asia (638,000) [44].  According to a review on 
the global burden of communicable diseases among 
people in prison, the HCV prevalence in Western 
Europe was estimated at 15.5% (12.2-19.1). When 
considering only prisoners with a history of IDU, na-
tional HCV estimates were largely above 40% [25].
 There are large parts of the world where no 
prevalence data is available such as Russia and its 
former states [44]. There is also very limited data on 
involuntary detainees (2 studies) [50, 74].
While many studies have reported on anti-HCV 
prevalence among prison and PWID populations [32, 
44], only a handful have reported on rates of chronic 
infection [47, 52, 72]. A number of studies report 
chronic HCV prevalence in subgroups e.g. cohorts 
being targeted for treatment or committal prisoners, 
but these study designs do not allow for accurate pop-
ulation estimates [47, 52]. 
It is important that these types of studies are con-
ducted since chronic infection is the only reliable in-
dicator of the levels of infection in a population [17]. 
If we continue to rely on anti-HCV prevalence stud-
ies, we will miss the impact of treatment and will not 
have accurate indicators for re-infection rates among 
those treated [60]. 
It is also important that incidence and preva-
lence studies are up to date and representative of the 
population being studied, since older studies and 
those using convenience sampling report higher anti-
HCV prevalence rates than newer randomised studies 
[44, 60].  Understanding and quantifying the level of 
HCV related liver disease is crucial to inform HCV 
treatment policy and strategy. 
3.2. Screening approaches and guidelines
Many international guidelines on PWID and 
prisoner health recognise the high HCV prevalence 
and low levels of HCV diagnosis, and recommend 
that HCV screening and treatment be made an inte-
gral part of health care systems where these patients 
attend [1, 24, 77]. 
Two approaches are taken in high-income coun-
tries to expand HCV testing. The irst is to specify 
the risk groups for testing. Targeted testing of persons 
belonging to risk groups and those with high HCV 
prevalence is likely to increase the number of HCV-
infected people identiied and referred for assessment 
and treatment [24, 77].  Risk group identiication is 
challenging because many individuals do not wish 
to acknowledge behaviours that are stigmatising [42, 
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77]. The second approach used is to deine demo-
graphic groups using age criteria. An example of this 
approach is birth-cohort testing in the USA [62]. 
WHO guidelines recommend the offering of 
HCV serology testing to individuals who are part of 
a population with high HCV prevalence or who have 
a history of HCV risk exposure/behaviour [77]. This 
includes both PWID and prisoners.  International rec-
ommendations also advise repeat screening in indi-
viduals with ongoing risk of re-infection, including 
after spontaneous clearance or successful treatment 
[21, 77].
The 2003 Centre for Disease Control (CDC) 
guidelines recommended the HCV screening of 
prisoners on a risk basis [3]. The CDC revised their 
guidance in 2013 to include all prisoners falling into 
the baby boomer age cohort (1945-1965) [21]. This 
cohort are at low risk of onward transmission, but at 
high risk of developing HCV related liver disease giv-
en the length of time they have the infection [62]. The 
US Preventive Task Force recommends that a history 
of incarceration should trigger HCV screening in the 
community [30]. 
Despite these recommendations and evidence 
that, when made available, HCV screening and treat-
ment can be safely and successfully provided in pris-
on settings, often prisoners return to their communi-
ties post incarceration unaware of their HCV status 
and untreated [60]. 
3.3. Barriers and enablers 
A number of qualitative studies have identiied 
a broad and unique range of barriers and enablers to 
HCV screening in PWID and prisoners [9, 41, 66, 79]. 
The inability of PWID to access testing and 
treatment facilities and discrimination against this 
socially marginalised group have been identiied as 
major barriers to care [66]. Systemic barriers identi-
ied include lack of consensus guidelines regarding 
who to screen and limited infrastructure, particularly 
in drug treatment centres and primary care [9]. Lack 
of knowledge and the asymptomatic nature of both 
the acute and chronic stages of the infection are also 
identiied barriers [79].
In prisoners, personal and institutional barriers 
have been identiied to explain low screening uptake 
[39, 40, 61]. These include prisoners' fears and lack 
of knowledge about HCV, lack of awareness about 
testing procedures, concerns about conidentiality 
and stigma, socioeconomics, substance use, mental 
health, unstable lifestyle, health beliefs and compet-
ing priorities [39, 61].
Institutional barriers include the organisation 
of testing procedures, inadequate pre- and post-test 
discussion, lack of appropriate approaches to offering 
testing, and lack of continuity of care on discharge 
and transfer [40, 61]. The cost of screening and more 
importantly the cost of treating those chronically in-
fected is a further barrier to prisons actively pursuing 
a systematic approach to HCV screening [40].
In both these groups, most HCV testing is main-
ly performed through venepuncture, either on site or 
by referral. Venous access can be poor, requires spe-
cialist staff and if only available in hospital setting 
can further increase stigma [36].
A number of enablers to HCV screening uptake 
have been identiied in both these groups. PWID are 
most likely to be successfully screened at locations 
where they are in contact with the health care system 
(on-site testing) [39, 81]. These include drug treat-
ment clinics, emergency departments and general 
practices. Screening is further enhanced by having 
pre-test counselling and education available at these 
sites [8].
Low-threshold facilities can serve as an initial 
point of HCV testing, utilising point-of-care (POC) or 
non-invasive such as dried blood spot testings (DBS) 
antibody tests [8]. A number of studies have reported 
that offering transient elastography in low-threshold 
facilities has the potential to raise awareness of liver 
health and facilitate HCV testing and management 
[81].
A 2014 systematic review reported that the pro-
vision of support and training to GPs, the offering of 
DBS and the provision of testing through outreach 
programmes may increase uptake of HCV testing in 
targeted populations [40]. There is also evidence that 
media-based interventions are effective in increasing 
the uptake of testing, identifying HCV-infected per-
sons and referring them to care [59].
Enablers to HCV screening in prisoners have 
been identiied and these include in-reach hepatology 
services, improved models of health care delivery, 
increasing prisoners’ awareness and understanding 
of HCV infection and treatment options, educating 
both operational and clinical staff and involvement of 
peer educators in increasing knowledge and reducing 
stigma [63, 73].
DBS is a non-invasive blood test and can be per-
formed by clinical and non-clinical staff. It necessi-
tates only a needle prick that requires minimal staff 
training. It is easy to perform in people with poor 
venous access so increasing opportunity for HCV 
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in the prison environment and have a positive impact 
on prisoner wellbeing [31]. 
Peer workers have the ability to connect with 
other prisoners, reduce social stigma and impact posi-
tively with a vulnerable patient cohort who is tradi-
tionally resistant to professional advice [67]. There 
are also direct beneits for the peer workers them-
selves and beneits for the wider prison system in-
cluding more effective use of resources and the ability 
to expand the range of prison-based health services 
available to inmates [2, 31]. The use of peer support 
workers in HCV assessment and prison-based health 
delivery initiatives is recognised in the literature as an 
effective facilitator to increase HCV screening uptake 
[2, 58].  
The importance of peer to peer education is well 
recognised. Peer education has been adopted in health 
promotion in various settings because of its cost-ef-
fectiveness over professionally delivered services [4]. 
Furthermore, peers are seen by other prisoners as a 
credible source of information and have the potential 
to address the lack of HCV related knowledge and 
stigma reported among prison populations [4]. 
3.6. Ethical Issues
The United Nations and the European court of 
human rights are increasingly inding that issues re-
lated to HCV and harm reduction in detention can 
contribute to or even constitute conditions that meet 
the threshold of ill treatment [54, 70]. These include 
the inadequate prevention care or treatment of HCV, 
the denial of harm reduction series or conditions that 
aggravate and favour the transmission of these dis-
eases [54, 70].
Prisoners are entitled to the equivalence of care 
and access to the highest attainable standard of physi-
cal and mental health [69]. The United Nations Basic 
Principles for the Treatment of Prisoners state that 
prisoners “shall have access to the health services 
available in the country without discrimination on the 
grounds of their legal situation" [10]. According to 
the WHO, national and regional governments should 
provide prisoners with the best possible healthcare 
free of charge, even in times of substantial economic 
dificulty [19].
Importantly, several ethical issues regarding 
HCV testing in prison have been raised. There is a 
need to ensure that HCV screening in prison is truly 
voluntary and not a result of coercion due to poten-
tially unequal power relationships between prisoners 
and staff [46].
screening. Two UK studies showed that offering DBT 
within specialist addiction services and prisons led to 
a threefold to six-fold increase in HCV screening [45, 
73].
Studies have shown that the use of oral POC tests 
in prisons have shown good uptake and acceptability 
and have demonstrated that these are cost-effective if 
followed up with treatment for those identiied has 
having chronic HCV infection [55].
3.4. Opt-out screening
Many previous guidelines recommend HCV 
screening in prisons based on prisoner self-request or 
self-reported risk factors (opt-in) which are vastly un-
derreported because of fear of self-incrimination and 
stigma [25, 42, 60]. Opt-out screening involves in-
forming the prisoners that a HCV screen will be per-
formed (usually as a suite of other blood tests) unless 
he/she opts-out or refuses testing [14, 42, 60]. This 
approach is already recommended by the CDC for 
HIV testing in incarcerated populations [26]. This ap-
proach has been shown to increase diagnosis, stream-
line screening procedures, reduce stigma, improve 
uptake in medical care and be cost-effective [26]. In 
the UK, opt-out screening is now the recommended 
approach to HCV screening in prisons [68]. It is vital 
that testing is voluntary, and that conidentiality be 
maintained as part of the approaches to enhance test-
ing [46, 68].
3.5. Peer Support 
Studies have shown that the use of peer workers 
in community-based HCV management has a positive 
impact on the uptake of services [58, 63]. Research 
shows high levels of satisfaction among service users 
and staff in community-based drug treatment clinics 
with this role [67]. 
There is further evidence to suggest that engage-
ment in HCV care may be facilitated by the inluence 
of peers who completed treatment [2]. The ETHOS 
Study in Australia reported a very strong positive 
response to peer workers by staff and service users 
which lead to improved access to services, a more 
client-friendly treatment environment and increased 
support to services users with assessment and en-
gagement with HCV treatment [58].
A large 2016 systematic review (mainly qualita-
tive studies) of peer education and support in prison 
settings found that peer education interventions are 
effective at reducing risk behaviour, acceptable with-
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become increasingly complex. There is substantial 
regional variation in the quality, comprehensiveness 
and organisational infrastructure of health-care deliv-
ery [29, 76]. There is much consensus in the medical 
literature that lack of emphasis and resourcing into 
the management of prisoner health is a wasted public 
health opportunity [76].
The Committee of Ministers of the Council of 
Europe has urged for prison health to be integrated 
into and compatible with national health policy, stat-
ing that such integration is in the best interests of the 
population at large, particularly for policies relating 
to infectious diseases [18].
Many countries have linked prison health and 
public health services. In Norway, France and the 
UK, the delivery of prison healthcare is under the au-
thority of the national public health department [23]. 
In the USA, where prison healthcare is overseen 
by both national and regional government, various 
healthcare delivery models are used [57]. These range 
from healthcare services being entirely run by prison 
staff to those in which contractual relations are estab-
lished with outside healthcare providers [57]. In some 
prison systems, academic medical centers play an im-
portant role in healthcare delivery, with evidence of 
improved outcomes [57].
Poor integration between prison and public 
health systems results in poor continuity of care for 
individuals transitioning to the community after re-
lease from prison [7]. Such fragmentation of care af-
fects prisoners with various disorders, such as HIV, 
mental illness, diabetes and asthma, and can result in 
delayed treatment and costly use of health care [7]. 
Jurisdictions in which healthcare is delivered 
under the auspices of correctional authorities face the 
essentially intrinsic conlict between custodial and 
healthcare priorities, whereas settings where health-
care is delivered by separate health agencies face the 
challenge of dealing with dual bureaucracies  [29, 76]. 
3.9. Moving between prison and community
Studies in Europe, Australia, and the USA have 
shown that inmates have a higher mortality after their 
release from prison [13, 16, 51]. The transition back 
to the community from prison is a stressful period, 
as released prisoners attempt to secure housing and 
employment and to re-connect with family. In many 
cases they have to cope with substance use and men-
tal health disorders. During this transitional period, 
they are especially likely to engage in high-risk sexu-
al activities and illicit substance use [13, 15, 16].
A recent court ruling in the USA ruled that pris-
ons cannot ignore HCV disease in prisons and also 
that those identiied as chronically infected should be 
provided with treatment [6]. These rulings could have 
a major impact on prison budgets and may reduce the 
appetite among prisons to screen for HCV. 
3.7. Cost-effectiveness
Despite low PWID treatment rates, upscaling 
HCV screening can be cost-effective in drug treat-
ment services and in prisons in high-income settings 
if continuity of treatment/care is ensured [29, 37]. 
The higher the treatment rates, the more cost-effec-
tive HCV screening becomes, as more of those iden-
tiied as chronically infected will be treated having a 
greater impact on the general population [37]. 
As previously reported, DBS is an effective 
targeted intervention for increasing HCV screening 
among PWID and prisoners [63, 73]. Studies have 
shown that DBS testing in addiction services and 
prisons is cost-effective [29, 37]. 
Under the base-case assumption of no continuity 
of treatment/care when exiting/entering prison, DBS 
testing is not cost-effective in prison settings [37]. In-
creasing PWID treatment rates to those for ex-PWID 
considerably reduces ICER (£4500 and £30 000 per 
QALY gained for addiction services and prison, re-
spectively). If continuity of care is >40%, the prison 
DBS ICER falls below £20 000 per QALY gained 
[37]. 
Economic evidence for screening populations is 
robust. If a cost per quality adjusted life year (QALY) 
of £30 000 is considered reasonable value for money, 
then screening birth cohorts, drug users and high-risk 
populations are cost-effective [37]. 
A 2016 American study using mathematical 
modelling found that universal opt-out screening in 
prisons is highly cost-effective and would reduce 
HCV transmission and HCV related morbidity and 
mortality both in prison and, in particular, in the com-
munity [37].
3.8. Prison Health Care Structures
There is huge variation globally in models of 
health care delivery which is often resource depend-
ent. Prison health care systems relect these variations 
and are further complicated by the competing needs 
of security [76]. 
With increasing global prison populations and 
disease epidemics, prison healthcare services have 
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is crucial. Opt-out screening on committal increases 
uptake and avoids prisoners having to declare a his-
tory of IDU [55]. It is important to ensure that opt-out 
screening remains voluntary without undue coercion 
or pressure [46]. 
Some prisoners may ind the initial committal 
time very distressing with many competing priori-
ties [39, 55]. Delaying screening in this situation to 
a later time when the prisoner is more settled may 
improve uptake. Many prisoners engage in on-going 
risk behaviour while incarcerated and ongoing repeat 
screening will be required for this cohort [24, 42, 47]. 
However similar to risk-based screening it will re-
quire the prisoners to admit to IDU. The use of peer 
educators both in community and prison settings may 
have an important role in building trust and the re-
duction/elimination of stigma for these marginalised 
groups [2, 31, 58, 67]. 
It is important to recognise that tackling the 
public health challenge of HCV infection requires 
linking both community and prison-based initiatives, 
understanding that most prisoners spend very short 
periods incarcerated and most PWID will spend time 
in prison [42, 65]. There is strong evidence to sug-
gest that transitioning from prison to community is 
a high-risk period for many prisoners including for 
HCV transmission [65].
It is also critical to understand that prisoners are 
not a homogenous group and within this cohort there 
is variable HCV risk, levels and severity of HCV re-
lated and other physical and mental health morbidi-
ties [29]. 
5. Conclusions
PWID and prisoners remain key target popu-
lations in the public health effort to eliminate HCV 
infection. HCV infected prisoners are by in large a 
subset of PWID and represent the most socially mar-
ginalised and underserved population in society. The 
beneits of HCV screening and treatment will have 
a much more positive impact on community public 
health and there is a strong argument for diverting 
funding into prison screening and treatment. Prisons, 
more than any other site, provide an excellent oppor-
tunity to diagnose and treat large numbers of the most 
marginalised and vulnerable people with chronic 
HCV infection that traditional medical services are 
failing to engage.
Because many PWID are incarcerated for rela-
tively brief periods (on average 4 months in the UK), 
it is crucial to ensure that infected individuals are re-
ferred to treatment and remain in referral contact or 
on treatment after release or transfer [5]. Those not 
treated while in prison can be referred to care in clini-
cal or community settings when released [5].
As previously reported the cost-effectiveness 
and beneits of enhanced prison screening is depend-
ent on treatment follow up on release [19, 37, 48].
4. Discussion
HCV infection is now a curable and prevent-
able epidemic, but major challenges exist to engag-
ing those most at risk of infection with screening and 
treatment services [39, 41].  Despite HCV incidence 
and prevalence being much higher in PWID and pris-
oners than the general population, there are substan-
tial deicits in HCV surveillance in most jurisdictions 
in these two groups [20, 22, 38, 44, 56]. This impacts 
the planning and implementation of national HCV 
strategies. 
Increasing HCV surveillance, in particular data 
on transmission risks, the prevalence of untreated 
chronic HCV infection and incident infection, is 
crucial to inform HCV management and prevention 
strategies, policy makers and budget holders.
Removing identiied barriers to HCV screening 
is the irst step in tackling the HCV epidemic.  Fo-
cusing screening efforts to locations where high-risk 
populations attend (drug treatment services and pris-
ons) will have the greatest impact [25, 81]. Providing 
a range of screening methods including venepuncture, 
POC oral and DBS testing will maximise uptake and 
allow for HCV screening provision across a range of 
locations, including those staffed by non-clinical per-
sonnel [55, 81]. 
Consideration needs to be given to simplifying 
testing regimes including relex testing of all samples 
shown to be anti-HCV positive [24]. The requirement 
for testing for other drug related blood borne viral 
(BBV) infections may determine the most suitable 
type of screening required. It is important that ser-
vices communicate with each other to avoid unnec-
essary testing and to prevent missed opportunities to 
progress patients along the HCV treatment-cascade. 
This is of particular importance when patients enter 
and exit prisons [5, 8, 39, 65]. 
Prison offers an opportunity to engage a subset 
of PWID that are dificult to engage in other loca-
tions [42]. Maximising this public health opportunity 
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